MTOR and chronic granulomatous disease: Rapamycin, a potent mammalian target of rapamycin (mTOR) inhibitor and autophagy inducer, has been shown to be able to restore autophagy and to regulate inflammasome activation in patients with CGD, unravelling new therapeutic opportunities for the treatment of inflammatory manifestations in CGD [16, 17].